Leucine-rich Alpha-2 glycoprotein is a serum biomarker of mucosal healing in ulcerative colitis

Shinichiro Shinzaki, Katsuyoshi Matsuoka, Hideki Iijima, Shinta Mizuno, Satoshi Serada, Minoru Fujimoto, Norimitsu Arai, Noriyuki Koyama, Eiichi Morii, Mamoru Watanabe, Toshifumi Hibi, Takanori Kanai, Tetsuo Takehara, Tetsuji Naka

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background and Aims: Although several noninvasive and easily accessible biomarkers for inflammatory bowel disease [IBD] are available, their sensitivity and specificity are not adequate to be used as single markers and do not overrule the need for endoscopic evaluation. We previously reported that serum leucine-rich alpha-2 glycoprotein [LRG] was a novel biomarker for rheumatoid arthritis and IBD. We herein investigated whether LRG could indicate endoscopic activity in patients with ulcerative colitis [UC]. Methods: Serum LRG concentrations were determined by enzyme-linked immunosorbent assay [ELISA] in consecutive 129 patients with UC in two tertiary care hospitals, and associations of LRG with clinical and endoscopic activities were evaluated. Clinical activity index [CAI] < 6 was defined as clinical remission, and mucosal healing [MH] and complete mucosal healing were defined as Matts' endoscopic grades of 1 or 2 and grade of 1, respectively. Results: Serum LRG levels were significantly increased and correlated with clinical and endoscopic activities in patients with UC. LRG levels were associated with both clinical and endoscopic activities even in patients with normal serum C-reactive protein [CRP] levels. Furthermore, LRG levels were significantly lower in patients with complete MH and deep remission. Serial measurements of LRG levels in a subset of patients demonstrated that LRG was significantly elevated during the endoscopically active stage compared with that during the MH stage. Conclusions: Serum LRG is a novel biomarker for detecting MH during disease course in patients with UC and a surrogate marker of endoscopic inflammation in patients with normal CRP levels.

Original languageEnglish
Pages (from-to)84-91
Number of pages8
JournalJournal of Crohn's and Colitis
Volume11
Issue number1
DOIs
Publication statusPublished - 2017

Fingerprint

Ulcerative Colitis
Leucine
Glycoproteins
Biomarkers
Serum
Inflammatory Bowel Diseases
C-Reactive Protein
Tertiary Healthcare
Tertiary Care Centers
Blood Proteins
Rheumatoid Arthritis
Enzyme-Linked Immunosorbent Assay
Inflammation
Sensitivity and Specificity

Keywords

  • Biomarker
  • C-reactive protein
  • Leucine-rich alpha-2 glycoprotein
  • Mucosal healing

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Shinzaki, S., Matsuoka, K., Iijima, H., Mizuno, S., Serada, S., Fujimoto, M., ... Naka, T. (2017). Leucine-rich Alpha-2 glycoprotein is a serum biomarker of mucosal healing in ulcerative colitis. Journal of Crohn's and Colitis, 11(1), 84-91. https://doi.org/10.1093/ecco-jcc/jjw132

Leucine-rich Alpha-2 glycoprotein is a serum biomarker of mucosal healing in ulcerative colitis. / Shinzaki, Shinichiro; Matsuoka, Katsuyoshi; Iijima, Hideki; Mizuno, Shinta; Serada, Satoshi; Fujimoto, Minoru; Arai, Norimitsu; Koyama, Noriyuki; Morii, Eiichi; Watanabe, Mamoru; Hibi, Toshifumi; Kanai, Takanori; Takehara, Tetsuo; Naka, Tetsuji.

In: Journal of Crohn's and Colitis, Vol. 11, No. 1, 2017, p. 84-91.

Research output: Contribution to journalArticle

Shinzaki, S, Matsuoka, K, Iijima, H, Mizuno, S, Serada, S, Fujimoto, M, Arai, N, Koyama, N, Morii, E, Watanabe, M, Hibi, T, Kanai, T, Takehara, T & Naka, T 2017, 'Leucine-rich Alpha-2 glycoprotein is a serum biomarker of mucosal healing in ulcerative colitis', Journal of Crohn's and Colitis, vol. 11, no. 1, pp. 84-91. https://doi.org/10.1093/ecco-jcc/jjw132
Shinzaki, Shinichiro ; Matsuoka, Katsuyoshi ; Iijima, Hideki ; Mizuno, Shinta ; Serada, Satoshi ; Fujimoto, Minoru ; Arai, Norimitsu ; Koyama, Noriyuki ; Morii, Eiichi ; Watanabe, Mamoru ; Hibi, Toshifumi ; Kanai, Takanori ; Takehara, Tetsuo ; Naka, Tetsuji. / Leucine-rich Alpha-2 glycoprotein is a serum biomarker of mucosal healing in ulcerative colitis. In: Journal of Crohn's and Colitis. 2017 ; Vol. 11, No. 1. pp. 84-91.
@article{d260986c81da4f7e97a4a774651ecf77,
title = "Leucine-rich Alpha-2 glycoprotein is a serum biomarker of mucosal healing in ulcerative colitis",
abstract = "Background and Aims: Although several noninvasive and easily accessible biomarkers for inflammatory bowel disease [IBD] are available, their sensitivity and specificity are not adequate to be used as single markers and do not overrule the need for endoscopic evaluation. We previously reported that serum leucine-rich alpha-2 glycoprotein [LRG] was a novel biomarker for rheumatoid arthritis and IBD. We herein investigated whether LRG could indicate endoscopic activity in patients with ulcerative colitis [UC]. Methods: Serum LRG concentrations were determined by enzyme-linked immunosorbent assay [ELISA] in consecutive 129 patients with UC in two tertiary care hospitals, and associations of LRG with clinical and endoscopic activities were evaluated. Clinical activity index [CAI] < 6 was defined as clinical remission, and mucosal healing [MH] and complete mucosal healing were defined as Matts' endoscopic grades of 1 or 2 and grade of 1, respectively. Results: Serum LRG levels were significantly increased and correlated with clinical and endoscopic activities in patients with UC. LRG levels were associated with both clinical and endoscopic activities even in patients with normal serum C-reactive protein [CRP] levels. Furthermore, LRG levels were significantly lower in patients with complete MH and deep remission. Serial measurements of LRG levels in a subset of patients demonstrated that LRG was significantly elevated during the endoscopically active stage compared with that during the MH stage. Conclusions: Serum LRG is a novel biomarker for detecting MH during disease course in patients with UC and a surrogate marker of endoscopic inflammation in patients with normal CRP levels.",
keywords = "Biomarker, C-reactive protein, Leucine-rich alpha-2 glycoprotein, Mucosal healing",
author = "Shinichiro Shinzaki and Katsuyoshi Matsuoka and Hideki Iijima and Shinta Mizuno and Satoshi Serada and Minoru Fujimoto and Norimitsu Arai and Noriyuki Koyama and Eiichi Morii and Mamoru Watanabe and Toshifumi Hibi and Takanori Kanai and Tetsuo Takehara and Tetsuji Naka",
year = "2017",
doi = "10.1093/ecco-jcc/jjw132",
language = "English",
volume = "11",
pages = "84--91",
journal = "Journal of Crohn's and Colitis",
issn = "1873-9946",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Leucine-rich Alpha-2 glycoprotein is a serum biomarker of mucosal healing in ulcerative colitis

AU - Shinzaki, Shinichiro

AU - Matsuoka, Katsuyoshi

AU - Iijima, Hideki

AU - Mizuno, Shinta

AU - Serada, Satoshi

AU - Fujimoto, Minoru

AU - Arai, Norimitsu

AU - Koyama, Noriyuki

AU - Morii, Eiichi

AU - Watanabe, Mamoru

AU - Hibi, Toshifumi

AU - Kanai, Takanori

AU - Takehara, Tetsuo

AU - Naka, Tetsuji

PY - 2017

Y1 - 2017

N2 - Background and Aims: Although several noninvasive and easily accessible biomarkers for inflammatory bowel disease [IBD] are available, their sensitivity and specificity are not adequate to be used as single markers and do not overrule the need for endoscopic evaluation. We previously reported that serum leucine-rich alpha-2 glycoprotein [LRG] was a novel biomarker for rheumatoid arthritis and IBD. We herein investigated whether LRG could indicate endoscopic activity in patients with ulcerative colitis [UC]. Methods: Serum LRG concentrations were determined by enzyme-linked immunosorbent assay [ELISA] in consecutive 129 patients with UC in two tertiary care hospitals, and associations of LRG with clinical and endoscopic activities were evaluated. Clinical activity index [CAI] < 6 was defined as clinical remission, and mucosal healing [MH] and complete mucosal healing were defined as Matts' endoscopic grades of 1 or 2 and grade of 1, respectively. Results: Serum LRG levels were significantly increased and correlated with clinical and endoscopic activities in patients with UC. LRG levels were associated with both clinical and endoscopic activities even in patients with normal serum C-reactive protein [CRP] levels. Furthermore, LRG levels were significantly lower in patients with complete MH and deep remission. Serial measurements of LRG levels in a subset of patients demonstrated that LRG was significantly elevated during the endoscopically active stage compared with that during the MH stage. Conclusions: Serum LRG is a novel biomarker for detecting MH during disease course in patients with UC and a surrogate marker of endoscopic inflammation in patients with normal CRP levels.

AB - Background and Aims: Although several noninvasive and easily accessible biomarkers for inflammatory bowel disease [IBD] are available, their sensitivity and specificity are not adequate to be used as single markers and do not overrule the need for endoscopic evaluation. We previously reported that serum leucine-rich alpha-2 glycoprotein [LRG] was a novel biomarker for rheumatoid arthritis and IBD. We herein investigated whether LRG could indicate endoscopic activity in patients with ulcerative colitis [UC]. Methods: Serum LRG concentrations were determined by enzyme-linked immunosorbent assay [ELISA] in consecutive 129 patients with UC in two tertiary care hospitals, and associations of LRG with clinical and endoscopic activities were evaluated. Clinical activity index [CAI] < 6 was defined as clinical remission, and mucosal healing [MH] and complete mucosal healing were defined as Matts' endoscopic grades of 1 or 2 and grade of 1, respectively. Results: Serum LRG levels were significantly increased and correlated with clinical and endoscopic activities in patients with UC. LRG levels were associated with both clinical and endoscopic activities even in patients with normal serum C-reactive protein [CRP] levels. Furthermore, LRG levels were significantly lower in patients with complete MH and deep remission. Serial measurements of LRG levels in a subset of patients demonstrated that LRG was significantly elevated during the endoscopically active stage compared with that during the MH stage. Conclusions: Serum LRG is a novel biomarker for detecting MH during disease course in patients with UC and a surrogate marker of endoscopic inflammation in patients with normal CRP levels.

KW - Biomarker

KW - C-reactive protein

KW - Leucine-rich alpha-2 glycoprotein

KW - Mucosal healing

UR - http://www.scopus.com/inward/record.url?scp=85019764256&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019764256&partnerID=8YFLogxK

U2 - 10.1093/ecco-jcc/jjw132

DO - 10.1093/ecco-jcc/jjw132

M3 - Article

C2 - 27466171

AN - SCOPUS:85019764256

VL - 11

SP - 84

EP - 91

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

SN - 1873-9946

IS - 1

ER -